Avita Medical (NASDAQ:RCEL) reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook as management said reimbursement conditions for its RECELL product are normalizing and demand patterns are becoming more consistent.
The regenerative medicine company posted first-quarter revenue of approximately $19.3 million, up 4% from the prior-year period and about 10% sequentially from the fourth quarter of 2025. President and Chief Executive Officer Cary Vance said the result represented the company’s highest quarterly revenue over the past year and reflected progress after a period focused on stabilizing the business.
